Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (10.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 10.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 08.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Principal Officers; Election of Directors; App |
| 15.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 06.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | on 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
Stammdaten
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Unternehmen & Branche
| Name | Praxis Precision Medicines, Inc. |
|---|---|
| Ticker | PRAX |
| CIK | 0001689548 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 6,80 Mrd. USD |
| Beta | 2,97 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -303,268,000 | -13.48 | 937,907,000 | 878,136,000 |
| 2025-09-30 | 10-Q | 0 | -73,934,000 | -3.36 | 396,388,000 | 343,505,000 |
| 2025-06-30 | 10-Q | 0 | -71,127,000 | -3.31 | 452,832,000 | 404,224,000 |
| 2025-03-31 | 10-Q | 0 | -69,296,000 | -3.29 | 478,736,000 | 439,214,000 |
| 2024-12-31 | 10-K | 8,553,000 | -58,679,000 | -10.21 | 483,110,000 | 445,450,000 |
| 2024-09-30 | 10-K | -51,910,000 | 382,666,000 | |||
| 2024-09-30 | 10-Q | 302,000 | -51,910,000 | -2.75 | 416,256,000 | 382,666,000 |
| 2024-06-30 | 10-K | -32,677,000 | 419,100,000 | |||
| 2024-06-30 | 10-Q | 357,000 | -32,677,000 | -1.74 | 441,063,000 | 419,100,000 |
| 2024-03-31 | 10-Q | 431,000 | -39,553,000 | -2.84 | 250,409,000 | 229,683,000 |
| 2024-03-31 | 10-K | -39,553,000 | 229,683,000 | |||
| 2023-12-31 | 10-K | 2,447,000 | -26,878,000 | -18.69 | 87,948,000 | 69,669,000 |
| 2023-09-30 | 10-Q | 468,000 | -24,632,000 | -2.72 | 106,725,000 | 86,756,000 |
| 2023-09-30 | 10-K | -24,632,000 | 86,756,000 | |||
| 2023-06-30 | 10-K | -34,312,000 | 105,625,000 | |||
| 2023-06-30 | 10-Q | 781,000 | -34,312,000 | -7.38 | 133,498,000 | 105,625,000 |
| 2023-03-31 | 10-K | -37,455,000 | 64,468,000 | |||
| 2023-03-31 | 10-Q | 683,000 | -37,455,000 | -10.58 | 98,383,000 | 64,468,000 |
| 2022-12-31 | 10-K | 0 | -41,173,000 | -69.65 | 115,128,000 | 76,106,000 |
| 2022-09-30 | 10-K | -43,945,000 | 105,163,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | Nemiroff Alex | Officer, General Counsel and Secretary | Open Market Sale | -977 | 193.23 | -188,788.64 | -7,4% | |
| 2025-11-20 | Nemiroff Alex | Officer, General Counsel and Secretary | Open Market Sale | -1,714 | 190.86 | -327,139.18 | -12,9% | |
| 2025-11-20 | Nemiroff Alex | Officer, General Counsel and Secretary | Open Market Sale | -9,100 | 194.30 | -1,768,130.00 | -69,6% | |
| 2025-11-20 | Nemiroff Alex | Officer, General Counsel and Secretary | Open Market Sale | -13,339 | 192.53 | -2,568,197.69 | -101,1% | |
| 2025-11-20 | Mastrocola Lauren | Officer, Principal Accounting Officer | Open Market Sale | -2,145 | 192.71 | -413,365.10 | -16,3% | |
| 2025-11-20 | Mastrocola Lauren | Officer, Principal Accounting Officer | Open Market Sale | -11,455 | 191.96 | -2,198,878.89 | -86,5% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -12,600 | 90.00 | -1,134,031.50 | -44,6% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -19,198 | 140.00 | -2,687,720.00 | -105,8% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -308 | 132.19 | -40,714.95 | -1,6% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -250,000 | 104.31 | -26,077,375.00 | -1026,1% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -27,287 | 101.00 | -2,755,987.00 | -108,4% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -447 | 91.04 | -40,694.97 | -1,6% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -487 | 131.64 | -64,107.95 | -2,5% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -559 | 100.11 | -55,961.10 | -2,2% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -1,363 | 92.03 | -125,440.98 | -4,9% | |
| 2025-10-16 | Adage Capital Management, L.P. | 10% Owner | Open Market Sale | -1,661 | 130.10 | -216,090.12 | -8,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.